Correlation Between Onco-suppressors PTEN and NM23 and Clinical Outcome in Patients With T1 Breast Cancer

LUCIANO IZZO¹, DANIELA MESSINEO², PIERFRANCESCO DI CELLO³, VIRGILIO NICOLANTI¹, ANTONIO STERPETTI¹, SARA IZZO⁴ and PAOLO IZZO¹

¹Pietro Valdoni Department of Surgery, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; ²Department of Radiological Sciences, Oncology and Pathology, Sapienza University, Rome, Italy; ³UOC Chirurgia Generale Frosinone-Alatri presso ASL Frosinone, Frosinone, Italy; ⁴Multidisciplinary Department of Medical-Surgical and Dental Specialties, Plastic Surgery Unit, Luigi Vanvitelli University of Campania, Naples, Italy

Abstract. Background: The aim of the present work was to evaluate the prognostic significance in patients with T1 breast cancer of tissue expression of the two oncosuppressors phosphatase and tensin homolog (PTEN) and non-metastatic clone 23 (NM23) as detected by immunohistochemistry. Materials and Methods: We prospectively analyzed 62 patients who underwent surgery for a T1 stage breast cancer. Expression of PTEN and NM23 was tested for correlation with clinical characteristics and clinical outcome. Results: Of the 62 patients considered for our study, 16 underwent mastectomy and 46 underwent conservative surgical treatment. The surgery was considered radical (R0) in all cases described. PTEN and NM23 expression was higher in patients with no lymph node metastases and no recurrent cancer at a mean follow-up of 36 months (range=6-48 months). This correlation was more evident when both PTEN and NM23 expression were highly expressed (p<0.0001). Conclusion: Low or lack of PTEN and NM23 immunohistochemical expression in cancer tissue is a risk factor for lymph node involvement and recurrent disease. It may represent a valid prognostic factor in planning therapy in patients who had surgery for T1 breast cancer.

The incidence of breast cancer has significant geographical variability. Survival rates are lower in developing countries. In the European Union, mortality is decreasing, with an annual reduction of 2.1%. One of the reasons for this trend is the increased prevalence of mammography screening (1). There is also an increasing prevalence of patients with a diagnosis of T1 breast cancer. Patients with T1 breast cancer represent an heterogeneous group with different clinical outcomes. Analysis of hormone receptors, proliferation indices, markers, and genomic analyses might allow several phenotypic characteristics of T1 breast cancer to be determined, allowing therapy to be adapted to the specific patient (2, 3).

Onco-suppressors represent a heterogeneous group with several functions, such as in cell apoptosis and interruption of the cell cycle in the case of irreparable DNA damage, inhibition of cell replication, and facilitation of cell contact inhibition. Phosphatase and tensin homolog (PTEN) gene is located on chromosome 10q23. PTEN encodes a lipid phosphatase of 403 amino acids that plays a key role in the regulation of the cell cycle and subsequent apoptosis mechanisms (4). PTEN gene mutations are associated with Cowden’s syndrome, characterized by multiple hamartomata and a high risk of breast, endometrial and thyroid carcinomas. In breast cancer it has been observed that while PTEN gene mutations are uncommon (less than 5%) (5), several immunohistochemical studies have shown that reduced expression of PTEN protein is present in 30-50% of patients with breast cancer (6).

Included in the category of metastasis-suppressor genes is non-metastatic 23 clone (NM23). Its gene expression is reduced in murine highly metastatic melanoma cell lines compared to their non-metastatic counterparts. The NM23-H1 gene product has been proposed to be a kinase involved in synthesis of nucleic acids, glucose and some lipid derivatives. The aim of the present work was to evaluate the prognostic significance of tumor tissue expression of PTEN and NM23 in patients with T1-stage tumors, as determined by immunohistochemistry. We tried to determine the correlation of tissue expression of PTEN and NM23 with...
other known prognostic factors such as axillary lymph node involvement, tumor size, histopathological grade, receptor status, and the clinical history of the patients.

**Materials and Methods**

**Study design.** We prospectively evaluated female patients who underwent surgery at our Department from February 2015 to February 2020 for T1 breast cancer detected by mammography screening (Figure 1). The characteristics of the tumor and the clinical outcome of the patients were correlated to the expression of PTEN and NM23 in the tumor tissue, detected by immunohistochemistry. The study was approved by the Ethical Committee of our University (Department approval 2014-516R). All patients gave written informed consent.

**Surgery.** All patients underwent sampling of axillary sentinel nodes. In the case of involvement of axillary lymph nodes, a complete axillary lymphadenectomy was performed. Quadrantectomy or mastectomy was performed according to the decision of the patients.

**Inclusion criteria.** Patients with a tumor diameter <2 cm (T1), ductal infiltrating histotype and no clinical evidence of metastatic disease at diagnosis who underwent radical surgical treatment of cancer (R0).

**Exclusion criteria.** Patients with tumor diameter larger than 2 cm; axillary lymph node enlargement at clinical examination; presence of local symptoms (pain, erythema); bilateral tumors.

**Immunohistochemistry.** The following antibodies were used for immunohistochemical analysis: anti-PTEN (monoclonal, 1:50 dilution; Spring Bioscience Corp, Pleasanton, CA, USA) and anti-NM23 (monoclonal, prediluted; ScyTek, Logan, UT, USA).

The immunohistochemical study was carried out on 4-μm-thick sections of tissue fixed in formalin and embedded in paraffin. The sections were collected on positively charged slides and placed in an oven for 5 min at 50°C and then they were dewaxed in xylol and rehydrated using an alcoholic series until they reached running water. The antigenic sites were highlighted by heat treatment using a microwave oven at 750 W, for 3 cycles of 5 min each, in a TRIS/EDTA citrate buffer solution, at pH 7.8 for both antibodies, followed by a cooling period of 20 min at room temperature. The endogenous peroxidases were then blocked with a 5-min bath in 3% hydrogen peroxide. After washing with distilled water, the sections were covered with diluted normal serum (UltraTEK HRP anti-polyvalent; SCYTEK), for 10 min and then incubated with 100 ml of primary antibody for 30 min for anti-NM23 and 60 min for anti-PTEN at room temperature. Each slide, after rinsing twice with phosphate-buffered saline (PBS) for 5 min each, was incubated with two/three drops of secondary biotinylated antibody (UltraTEK HRP anti-polyvalent; SCYTEK) and after rinsing with PBS was incubated for 10 min with two to three drops of serum containing the avidin/biotin complex (UltraTEK HRP anti-polyvalent; SCYTEK). After again rinsing with PBS, the sections were incubated for 5 min with chromogen substrate solution, diaminobenzidine (DAB, UltraTEK HRP anti-polyvalent; SCYTEK) and finally were counterstained in hematoxylin for 10 s, dehydrated in an increasing alcohol series, clarified in xylol and mounted in synthetic resin.

The expression of PTEN was measured as follows: Score 0: absent; score 1: average positivity; score 2: intense positivity (normal). The expression of NM23 was measured as follows: Score 0-3: no or slight expression (<5% of cells); score 4-6: moderate expression (5-75% of cells); score 7-9: intense expression (>75% of cells; normal). The immunohistochemistry score was assessed independently by two examiners who did not know the histological and clinical characteristics of the patients. There was no discordance between the two examiners.

**Correlation of PTEN and NM23 expression and histological and clinical parameters.** The clinicopathological parameters correlated with PTEN and NM23 expression were: i) T1 stage: T1mic, microinvasion <0.1 cm in maximum size; T1a, between 0.1 cm

| Characteristic                                      | Value          |
|----------------------------------------------------|----------------|
| Age, years                                         | 57 (30-85)     |
| Surgery, n (%)                                      |                |
| Quadrantectomy                                      | 46 (74.19%)    |
| Mastectomy                                         | 16 (25.80%)    |
| Adjuvant therapy, n (%)                            |                |
| Total                                              | 48 (91.89%)    |
| Chemotherapy                                       | 11 (21.15%)    |
| Hormonotherapy                                     | 22 (42.30%)    |
| Chemohormonotherapy                                | 9 (17.30%)     |
| Trastuzumab                                        | 6 (17.64%)     |
| Tumor size, n (%)                                  |                |
| T1a                                                 | 6 (9.67%)      |
| T1b                                                 | 12 (19.35%)    |
| T1c                                                 | 44 (74.19%)    |
| Lymph nodes, n (%)                                 |                |
| N+                                                  | 13 (21.97%)    |
| N−                                                  | 49 (79.03%)    |
| Grading, n (%)                                      |                |
| 1                                                   | 19 (30.64%)    |
| 2                                                   | 32 (51.62%)    |
| 3                                                   | 11 (17.74%)    |
| Estrogen receptor, n (%)                           |                |
| Positive                                           | 41 (66.12%)    |
| Negative                                           | 21 (33.88%)    |
| Progesterone receptor, n (%)                       |                |
| Positive                                           | 40 (64.51%)    |
| Negative                                           | 22 (35.48%)    |
| HER2, n (%)*                                       |                |
| Positive                                           | 20 (32.26%)    |
| Negative                                           | 42 (67.74%)    |
| Receptor status overall, n (%)                     |                |
| Triple-negative                                     | 6 (11.53%)     |
| Status at end of study follow-up                   |                |
| Alive                                              | 55 (88.7%)     |
| Disease-free                                       | 49 (89.09%)    |
| With recurrence                                    | 6 (10.91%)     |
| Lost to follow-up                                  | 7 (11.3%)      |

HER2: Human epidermal growth factor receptor 2. *As evaluated by immunohistochemistry.
and 0.5 cm; T1b, between 0.6 cm and 1 cm; and T1c, between 1.1 cm and 2 cm, according to the seventh edition of the American Joint Committee on Cancer (2019) (7); ii) Histopathological degree; iii) Status of hormonal receptors and human epidermal growth factor receptor 2 (HER2); iv) Presence of lymph node metastases at final histology; v) Locoregional recurrence or distant metastasis.

Differences were analyzed by Fisher test, chi-squared test and multivariate analysis.

Results

Sixty-two patients were included in the study. The age of the patients ranged from 30 to 85 years (median of 57 years). Follow-up ranged from 4 to 48 months (mean=36 months). Sixteen patients underwent mastectomy and 46 underwent conservative surgical treatment. Surgery was considered radical (R0) in all cases. Table I shows the clinical characteristics of the patients.

PTEN immunohistochemical expression was normal (score 2) in 32 patients (51.61%), and reduced or absent (score 0-1) in 30 (48.39%). NM23 was overexpressed (score 7-9) in 34 patients (54.84%); in 19 cases (30.64%) the immunoreactivity was medium (score 4-6), and in nine (14.52%) it was low or absent (score 0-3). At a mean follow-up of 36 months, 55 patients were alive and free of disease, while seven were lost to follow-up. PTEN expression was reduced or absent in 18 cases and normal in 27; NM23 was of high intensity in 28 cases, medium intensity in 12 and low intensity or absent in four. There was no statistically significant difference between severity of the disease and positivity for PTEN and NM23. Immunohistochemistry showed higher levels of PTEN and NM23 expression in patients with no lymph node involvement and no evidence of recurrent disease, without reaching a statistically significant p-Value (p>0.99). However, the simultaneous evidence of high levels of PTEN and NM23 was statistically

Figure 1. Screening mammography in a 56-year-old showing glandular distortion in the right breast, T1C, with lymph node involvement. A: Craniocaudal view. B: Mediolateral oblique view.
correlated with less lymph node involvement in both univariate and multivariate analyses \((p<0.01)\) (Figures 2-5).

Six patients (13.97\%) developed a local relapse of the disease. Six patients were diagnosed with axillary lymph node metastases; in four of them PTEN and NM23 were both absent (score 0). In the other two patients, NM23 and PTEN were both expressed but at medium-low intensity (score 6 and 1 respectively) \((p<0.01)\).

\section*{Discussion}

Several reports have already analyzed the immunohistochemical expression of PTEN and NM23: these studies analyzed the correlation of each marker separately, including mainly patients with breast tumors in advanced stage. In these studies, a significant association between reduced PTEN expression and lymph node metastases was evident (13, 16, 17). A significant correlation between PTEN loss and negativity for estrogen (ER) and progesterone (PR) receptors has been documented (8). Knowles \textit{et al.} (9) found that the loss of PTEN was significantly associated \((p<0.001)\) with the basal-like phenotype (ER\(^-\), PR\(^-\), HER2\(^-\), CK5/6\(^+\) and EGFR\(^+\), CK5/6\(^+\) or EGFR\(^+\)), while a high expression was more often evident in patients with the luminal A phenotype (ER\(^+\) and PR\(^+\), ER\(^+\) or PR\(^+\), HER2\(^-\)) (9, 10).

Loss of PTEN has also been associated with resistance to tamoxifen and trastuzumab (10). The expression of NM23 has
been evaluated predominantly on metastatic cell lines. Bal et al. studied the immunohistochemical expression of NM23 in several benign and malignant epithelial lesions of the breast. They found a progressive down-regulation of NM23 as the tumor progressed to a metastatic stage (11). This inverse correlation between loss of NM23 and the presence of lymph node metastases has also been demonstrated by others: Tokunaga et al. \(p<0.01\) (12), Heimann et al. \(p<0.05\), and Royds et al. \(p<0.01\) (14).

The objective of our study was to determine the correlation between immunohistochemical expression of PTEN and NM23 and clinical outcome in patients with early stage breast cancer (stage T1). Sixty percent of patients with breast cancer and axillary lymph node involvement were found to be PTEN-negative \(p<0.001\) with a recurrence rate of 57% within 5 years (8, 15-18).

Reduced or absent immunohistochemical expression of PTEN in our study was found in 48.39% out of 62 cases of T1 invasive breast cancer: 13 patients had lymph node metastases at diagnosis and 69% showed reduced or absent immunohistochemical expression of PTEN. Four patients with lymph node involvement and immunohistochemistry negative for PTEN developed a local relapse of the disease within 5 years of surgery. These differences did not reach statistical significance \(p>0.99\) due to the small number of patients.

Regarding lymph node status, out of 32 patients with N0 disease, none presented a complete loss of NM23 – it was normally expressed in 22 cases (66%) and moderately) in 10 cases (34%). On the other hand, in out of 14 patients with N+ disease, NM23 was absent or weakly expressed in eight cases (60%) and normal only in one case. Charpin et al. showed NM23 expression >3% to be correlated with improved metastasis-free survival in patients with positive and those with negative lymph nodes (19). Heimann et al. documented a disease-free survival of 91% at 5, 10 and 15 years in patients with normal expression of NM23 and 70% in those with low expression \(p<0.008\) (13).

While PTEN gene mutations are uncommon in patients with breast cancer (less than 5%) (5), several immunohistochemical studies have shown that reduced expression of the PTEN protein is present in 30-50% of such patients (6). Most studies have included patients with advanced breast cancer. In these patients, there is the possibility that the expression of PTEN and NM23 may be related to other intervening factors, which may influence the level of expression of the two oncosuppressors. Phenotypic expression of these two oncosuppressors is correlated to tumor microenvironmental factors, including cell death-related acidosis, inflammation and cytokine release, and the factors favoring phenotypic expression are difficult to determine in advanced tumors (9).

In early-stage breast cancer, the expression of PTEN and NM23 is conceptually less related to the surrounding microenvironment. We found a significant correlation of the simultaneous reduced expression of PTEN and NM23 with lymph node involvement and possibility of recurrent disease.

Conclusion

The introduction of new prognostic factors into clinical practice may improve the results of personalized therapy in patients with T1 breast cancer. On the basis of the results of our study we can conclude that in patients with T1 breast cancer, the simultaneously reduced expression of PTEN and NM23 in cancer tissue might be an important prognostic factor predicting the development of a recurrence of the disease.

Conflicts of Interest

The Authors declare that they have no conflicts of interest.

Authors’ Contributions

Luciano Izzo supervised the research design, interpretation of the data and contributed to editing the article. Daniela Messineo participated in the data acquisition and contributed to editing the article. Pierfrancesco Di Cello, participated in the data acquisition. Virgilio Nicolanti participated in the data acquisition. Antonio Sterpetti contributed to writing and editing the article. Paolo Izzo mainly acquired and analyzed the data and wrote the draft and designed the research. All Authors participated in critical revision of the article for important intellectual content.

References

1. Sancho-Garnier H and Colonna M: Breast cancer epidemiology. Presse Med 48(10): 1076-1084, 2019. PMID: 31706896. DOI: 10.1016/j.pmed.2019.09.022X
2. Li X, Wang Q, Fu L, Liu M and Yu X: Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and the correlation among them. Zhong Nan Da Xue Xue Bao Yi Xue Ban 40(9): 973-978, 2015. PMID: 26408616. DOI: 10.11817/j.issn.1672-7347.2015.09.005
3. Stankovic T, Milinkovic V, Bankovic J, Dinic J, Tanic N, Dramicanin T and Tanic N: Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples. Biomed Pharmacother 68(5): 521-526, 2014. PMID: 24767865. DOI: 10.1016/j.biopha.2014.03.014
4. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E and Chibbar R: Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 18(2): 250-259, 2005. PMID: 15475931. DOI: 10.1038/modpathol.3800296
5. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu SJ, Barrera JA, Burgues O, Luich AM, Chen H, Hortobagyi GN, Mills GB and Meric-Bernstam F: PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10(6): 1093-1101, 2011. PMID: 21490305. DOI: 10.1158/1535-7163.MCT-10-1089
